Daiichi Sankyo and Merck Introduce Breakthrough Raludotatug Deruxtecan for the Treatment of Ovarian Cancer
Daiichi Sankyo and Merck have introduced Raludotatug Deruxtecan (R-DXd) as an investigational therapy that has received FDA Breakthrough Therapy Designation for the treatment of adult patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 who have previously received treatment with bevacizumab.
Raludotatug Deruxtecan is a potential first-in-class CDH6-directed DXd antibody-drug conjugate (ADC), engineered to selectively bind CDH6-expressing tumor cells. The therapy delivers a topoisomerase I inhibitor payload via a cleavable linker, inducing targeted tumor cell death while sparing healthy tissue, with the aim of improving clinical outcomes in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers.
The FDA’s Breakthrough Therapy Designation recognises the potential of Raludotatug Deruxtecan to deliver meaningful clinical benefit in patients with CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. This therapy is the first CDH6-directed investigational treatment to receive FDA Breakthrough designation, representing a significant milestone in precision oncology.
Ovarian cancer affects over 324,000 women worldwide each year. For patients with advanced disease, median overall survival after recurrence can be as short as two years, and the five-year survival rate for those with distant-stage cancer is approximately 32%.
Ovarian, primary peritoneal, and fallopian tube cancers are aggressive malignancies often associated with poor prognosis and limited treatment options. Patients with platinum-resistant disease experience rapid progression following standard chemotherapy, highlighting a substantial unmet medical need.
Raludotatug Deruxtecan is now positioned as a first-of-its-kind investigational therapy in this setting, offering hope for improved outcomes in a population with few available therapeutic options.
